GSKGlaxoSmithKlineSigning up patients
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Gastrointestinal Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 346 (planned)
- Started
- Jun 11, 2025
- Main results expected
- Jan 9, 2029
- Fully finished
- Jan 9, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (ORR)
Measured over: Up to approximately 22 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06885034 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC